IRE1 RNase inhibitor 8866 (MKC8866, MKC-8866) is a spectific small molecule inhibitor of mammalian IRE1 RNase activity, prevents the recombinant IRE1 protein from cleaving the synthetic XBP1 RNA probe.

JG-98 is an allosteric Hsp70 inhibitor, displays >3-fold more active, greater stability than MKT-077 against the breast cancer cell lines MDA-MB-231 and MCF-7 (EC50 of 0.4 uM and 0.7 uM, respectively).

Regadenoson is the first selective A2A receptor agonist that is approved by the FDA and is currently used clinically.

RU-301 (RU301) is a small molecule pan-TAM inhibitor that targets the TAM Ig1-Gas6 interface, blocks Gas6-dependent TAM activation.

Topiroxostat(FYX-051) is a novel and potent xanthine oxidoreductase (XOR) inhibitor with IC50 value of 5.3 nM.

A small-molecule IAP antagonist that binds to select baculovirus IAP repeat (BIR) domains resulting in dramatic induction of auto-ubiquitination activity and rapid proteasomal degradation of c-IAPs.

Ornipressin is a vasoconstrictor, haemostatic and renal agent.

Smurf1-IN-A01 is an inhibitor of negatively regulatory factor Smurf1 for promoting bone formation.

FKBP12 PROTAC dTAG-13 (dTAG-13) is an in vivo-active heterobifunctional adation tag (dTAG) small molecule that engage FKBP12F36V and CRBN, selectively degrade FKBP12F36V in a CRBN-dependent manner in cells.

FKBP12 PROTAC dTAG-7 (dTAG-7) is a cell-permeable heterobifunctional adation tag (dTAG) small molecule that engage FKBP12F36V and CRBN, selectively degrade FKBP12F36V in a CRBN-dependent manner in cells.

SRA737 is a highly potent, selective, ATP-competitive inhibitor of Chk1 with IC50 of 1.3 nM.

DJ101is a potent and metabolically stable tubulin inhibitor that can circumvent the drug efflux pumps responsible for multidrug resistance of existing tubulin inhibitors.

ACT-389949 is a novel potent and selective formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX) agonist with EC50 of 3 nM, shows potential for the treatment of inflammatory disorders..

ADH-503, reduced myeloid cell recruitment and altered the phenotypes of myeloid cells within the tumor. ADH-503 treatment increased responses to chemotherapy or radiation and also rendered normally resistant tumors sensitive to checkpoint blockade, as T c

BRITE338733 is a novel ATPase inhibitor.

cFMS Receptor Inhibitor II is a cell-permeable anilinoquinoline compound that acts as a strong, active site-targeting inhibitor of MCSF receptor/cFMS.

D3263 is a novel, orally bioavailable small molecule Trp-p8 agonist.

GSK461364 is a potent small molecule Polo-like kinase 1 (PLK1) inhibitor with a Ki of 2.2 nM.

SB297006 is a CCR3 antagonist, which significantly inhibits proliferation and neurosphere formation in CCL11-treated neural progenitor cells.

Ingliforib is a glycogen phosphorylase inhibitor, with IC50s of 52, 352 and 150 nM for liver, muscle and brain glycogen phosphorylase, and has cardioprotective activity.

JBSNF-000088 (6-Methoxynicotinamide) is a small molecule nicotinamide analog that inhibits Nicotinamide N-methyltransferase (NNMT) with IC50 of 1.8, 2.8 and 5.0?μM for human, monkey and mouse NNMT, respectively.

KY-226 (KY226) is a potent, allosteric, orally active inhibitor of protein tyrosine phosphatase 1B (PTP1B) with IC50 of 0.28 uM (human PTP1B), does not exhibit PPARγ agonist activity.

Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling.

ML367 is a potent inhibitor of ATPase family AAA domain-containing protein 5 (ATAD5) stabilization, acts as a probe molecule that has low micromolar inhibitory activity.

MRT-68921 hydrochloride (MRT68921) is a potent, relatively specific inhibitor of both ULK1 and ULK2 with IC50 of 2.9 and 1.1 nM, respectively.

CP-945598 HCl is a potent and selective cannabinoid type 1 receptor antagonist with Ki of 0.7 nM.

PDM 11 is a potent and selective aryl hydrocarbon receptor (AhR) antagonist.

PF 3845 is a selective fatty acid amide hydrolase (FAAH) inhibitor (Ki = 0.23 uM).

Pirozadil is a hypolipidemic agent.

PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 by covalent cysteine modification, without compromising DNA binding.